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The intrapartum prevention of group B streptococcus (GBS) bacterial infection in the newborn is based 
on Centers for Disease Control and Prevention (CDC) guidelines published1 in 2002 that require 
universal antepartum screening. An antepartum culture is to be obtained between 35 to 37 weeks' 
gestation from the vaginal to rectal area; the culture can be safely obtained by the woman herself. 
Vaginal cultures alone yield only 60% of the GBS identified, compared to those taken from both the 
vagina and rectum,2hence the guidelines require sampling from both areas. The CDC guidelines require 
intrapartum antibiotic prophylaxis (IAP) to be delivered intravenously by the nursing staff if the 
woman's culture is positive for GBS or if she has a preexisting risk factor that would indicate the need 
for IAP without testing for the presence of GBS colonization. Intrapartum antibiotic prophylaxis was 
based on 5 controlled trials that support efficacy of the approach in reducing neonatal GBS infection.3 
The guidelines were specifically intended to reduce the rate of early onset group B streptococcus 
(EOGBS) disease, which is associated with significant newborn mortality and morbidity with profound 
sequelae. Early onset group B streptococcus infections occur in the first week of life; prevention has 
presented a major challenge in perinatal nursing practice. When neonatal EOGBS disease occurs, it has 
a 5% to 10% mortality rate.4 The implementation of the 2002 CDC guidelines1 has reduced the overall 
incidence of invasive neonatal EOGBS infection. For example, in one study5 that included 5 states, the 
rates of EOGBS declined from 0.47 cases per 1000 live births in 1999–2001 to 0.34 cases from 2003–
2005, which amounts to a 27% reduction. Compared to a decade earlier, when the rate in 1993 was 
reported to be 1.7 cases per 1000 live births, the decreased incidence of EOGBS disease is even more 
evident. To further reduce EOGBS disease, adherence to the GBS guidelines based on antepartum test 
results, with IAP given to appropriate candidates, has important risk management considerations. It 
was estimated that timely administration of IAP could prevent as much as 80% of perinatal GBS 
infections.6 A portion of the EOGBS residual infections may be related to the approximately 4% of 
women with false-negative cultures during the third trimester.7Another smaller portion of the EOGBS 
infections could be due to nonadherence to the GBS guidelines.8 
SOURCE OF GBS 
Early onset group B streptococcus infections are almost exclusively the result of vertical transmission 
from the mother.9 Fully, 80% of all the neonatal GBS infections1 are early onset and associated with a 
significant portion of the GBS-related mortality.4 (Late onset GBS disease, defined as occurring from 1 
week up to 3 months (89 days) after birth, is differentiated as a separate entity, is not addressed in the 
CDC guidelines,1 and is beyond the scope of this article.) 
Independent of hygiene, most vaginal bacteria originate and ascend from intestinal microbes.10 Group 
B streptococcus is normal flora present in the gastrointestinal track and vaginas of 10% to 30% of 
women. Variation is noted by ethnicity, with African American women having higher rates of GBS-
positive cultures (up to 40.6%) and heavier colonization than women of other ethnic groups.11 Heavier 
colonization is directly related to the risk of giving birth to a GBS-colonized infant.11 Group B 
streptococcus colonization may be transient, intermittent, or chronic.1,12 In healthy pregnant women, 
this normal flora may be vertically transmitted to infants during birth and lead to EOGBS infections 
even if the amniotic membranes are intact.13 Of colonized women, it is estimated that the rate of 
maternal-neonatal transmission is 1% to 2%, with 3% to 12% of neonates developing bacteremia 
resulting in EOGBS disease.4 
INTRAPARTUM ANTIBIOTIC PROPHYLAXIS 
On the basis of the population incidence of colonization, the universal testing approach potentially 
results in IAP exposure for 10% to 40% of laboring women. Penicillin (PCN) G is the preferred antibiotic 
for IAP; ampicillin can be used to replace PCN, but not if the woman has a PCN allergy. Alternative 
antibiotic selection is based on a history of allergies and GBS susceptibility to various antibiotic agents. 
The other medications that can be substituted in particular situations are erythromycin, clindamycin, 
cefazolin, or vancomycin. For women with PCN allergies who are at low risk of anaphylaxis, cefazolin is 
the recommended IAP agent.6 If the PCN-allergic woman's culture results indicate resistance or 
susceptibility is unknown, vancomycin is indicated.6 
Antibiotic resistance is a growing concern especially for PCN-allergic women.6 Thus far, a less than 2% 
resistance to PCN has been reported.14 However, 2 of the substitutes for PCN-allergic women, 
erythromycin and clindamycin, are increasingly associated with GBS resistance.6,15 Therefore, routine 
testing for antibiotic susceptibility is recommended when women are not PCN 
candidates.16,17 Regardless of the chosen medication for IAP, nursing responsibilities include 
monitoring for allergic reactions to the agent administered. 
According to the 2002 CDC guidelines,1 optimal prophylaxis is 4 hours prior to birth.6 If labor continues 
beyond that point, the guidelines direct that IAP be repeated every 4 hours. Several studies have 
shown that the 4-hour time frame was not scientifically determined. Colombo and 
colleagues18 examined 21 women with scheduled cesarean sections who received intravenous 
ampicillin before delivery and agreed to simultaneous blood sampling when the newborn cord blood 
was drawn at birth. The shortest IAP to birth time was 27 minutes; by that time, the bactericidal level 
in the cord blood was adequate. The bactericidal levels continued to increase in a linear relationship up 
to 5.6 hours following dosing, which was the longest interval to delivery in the study.18 Illuzzi and 
Bracken19 conducted a systematic review of 4 studies and found that the incidence of GBS-colonized 
neonates born to GBS-positive mothers decreased substantially within 1 to 2 hours of IAP. The authors 
added that the pharmacokinetic data did not support the rationale for the 4-hour time frame. Bloom 
and associates20 documented that bactericidal concentrations of ampicillin in fetal and maternal blood 
were reached within 3 minutes and in amniotic fluid within 5 minutes during elective cesarean 
sections. Thus, invasive newborn testing and separation from mothers for extended observations may 
not be indicated when IAP was administered less than 4 hours prior to birth. 
CONTINUED CHALLENGES 
While IAP for women colonized with GBS has successfully reduced the incidence of EOGBS, it is not 
without consequences. The 2002 CDC guidelines1 include treatment of GBS-positive women with IAP; 
however, the problem of neonatal EOGBS infections has not been eradicated. 
Mortality is significantly higher in preterm infants, with prematurity accounting for two thirds of all 
GBS-related deaths.4 Therefore, a woman who is in active preterm labor with an unknown GBS status, 
and expected to deliver preterm, should receive IAP. Given that women with a late preterm infant do 
not commonly receive tocolytic agents and the course of labor may be rapid, there is a risk that GBS 
prevention may not occur. 
Group B streptococcus can be identified on routine urine cultures done any time during pregnancy. The 
incidence of antenatal GBS bacteriuria is estimated9 at 2% to 4%. Prompt treatment of the urinary tract 
infection following diagnosis is necessary. Group B streptococcus cultures during the third trimester 
are not indicated for women affected with GBS bacteriuria; they are considered heavier colonizers of 
GBS and require IAP because their infants are at greater risk of EOGBS infections.1 The same holds true 
for a woman who has given birth previously to an infant with an invasive GBS infection. These mothers 
are also considered heavier colonizers and therefore at high risk of transmitting GBS to subsequent 
neonates; they are to receive IAP without the need for antepartal culturing.1 
The intrapartum care of a woman with unknown GBS status presents an additional challenge for nurses 
and other healthcare providers. When the GBS status is unknown, the woman should be treated using 
a risk-based approach.1 When a culture was not obtained prenatally or the result is unknown, women 
who have one of the following risk factors should receive IAP: (1) less than 37 weeks' gestation with 
anticipation of delivery, (2) rupture of membranes greater than or equal to 18 hours, and (3) maternal 
temperature greater than or equal to 100.4°F. Women who have unknown GBS status without any risk 
factors should not receive IAP. Conversely, IAP is not indicated when women have a negative GBS 
culture in the third trimester, even if an intrapartum risk factor develops.1 
ONGOING NEONATAL CONCERNS 
The symptoms of EOGBS include respiratory instability, apnea, lethargy, and hypotension.21 These 
symptoms manifest quickly. For example, a study of 277 912 live births identified 172 infants with 
positive GBS cultures and clinical signs of EOGBS infection. Of these, 95% were symptomatic within 24 
hours, another 3.7% within 48 hours, with only 1.2% demonstrating symptoms after 48 
hours.22 Therefore, the vast majority of EOGBS infections will be detectible within one day of life.22 In 
affected neonates, bacteremia, meningitis, and pneumonia may result. Approximately, 5% of neonatal 
bacteremia is thought to be nosocomial in origin,4 highlighting the nursing responsibility of careful 
hand washing during client care. 
While IAP is protective, it is not without neonatal consequences. Ampicillin is a broad spectrum 
antibiotic, and therefore is more likely to lead to problems with antibiotic resistance. Although data are 
based on a small number of cases, the incidence of Escherichia coli bacteremia appears to have 
increased, especially in very low-birth-weight neonates.4 This may be attributable to ampicillin 
resistant E coli strains, but evidence linking it specifically to IAP is lacking.4 Intrauterine exposure to 
broad spectrum antibiotics may alter the neonatal gut flora in ways that might have long-term effects 
and could be related to the development of allergic sensitivity.23 
CLINICAL IMPLICATIONS 
Pinto and colleagues24 speculated about multiple causes of residual cases of EOGBS infections despite 
the use of the CDC guidelines.1 These included confusion about existing guidelines, lack of access to 
GBS culture results on admission, rapid labor progress, and maternal refusal of IAP. Knowledgeable 
perinatal nurses can impact the first two issues and use careful documentation to explain the lack of 
IAP for the latter two. 
Several strategies can improve adherence to the CDC guidelines1 and therefore reduce residual cases 
of EOGBS. For example, preprinted orders can streamline the initiation of IAP. The intrapartum nurse 
needs to locate the culture result and also confirm when the specimen was collected. Group B 
streptococcus culture results taken 6 weeks or more prior to birth have only a 43% sensitivity and a 
85% specificity. This is contrasted with cultures taken between 1 to 5 weeks prior to delivery that have 
a 87% sensitivity and a 96% specificity.7 
Adherence to the 2002 CDC guidelines1 has resulted in a significant decrease in EOGBS infections. One 
concern for women and nurses is the timing of IAP. Penicillin and ampicillin are the only recommended 
antibiotics that require redosing every 4 hours until birth. On the basis of the studies of ampicillin 
administration that identified that bacteriocidal levels were rapidly achieved in both the mother and 
fetus following IAP, a woman can be reassured that she is likely adequately prophylaxed prior to the 4-
hour time frame suggested in the guidelines.18 Further, if there is a delay in administering a repeat IAP 
dose, Colombo and colleagues18 documented bactericidal concentrations up to 5.6 hours post-IAP. The 
antibiotics appropriate for PCN-allergic women are given every 6 to 12 hours, depending on the agent 
used.1 This knowledge can be shared with women. Because women can become ill with 
chorioamnionitis, endometritis, postpartum wound infections, and septicemia as a result of GBS,25 IAP 
also may avert serious maternal infections. 
FUTURE DIRECTIONS 
Nurses need to remain current as guidelines and diagnostics change. For example, a rapid GBS test 
done during intrapartum care may improve detection of GBS colonization at the time of birth.8 A 
maternal GBS vaccine is in development but far from use in the general population.26 While it is true 
that in the future GBS management may change, lack of adherence to the current prevention 
guidelines is not optional. 
Creative approaches are needed to further eliminate the incidence, and the profound consequences, 
of residual cases of neonatal EOGBS disease. Despite the successes attributable to the current 
guidelines, the amount of treatment required and the related costs cannot be ignored. Furthermore, 
the long-term consequences of IAP, including repeated dosing, for women and infants have not been 
documented. The use of IAP alters normal birth for almost one third of all women. Just the necessity of 
an intravenous catheter can create an atmosphere that medicalizes the experience. In addition, 
parents worry about GBS throughout late pregnancy and birth, particularly in terms of the timing of 
their entry into the birth environment to receive IAP. The parents' emotional issues associated with 
GBS colonization warrant investigation. Facilitating IAP in an out-of-hospital birth setting adds 
technologic complexity. For example, home birth practitioners must transport the necessary 
equipment and supplies. The cumulative impact of GBS colonization on normal birth processes needs 
investigation. These authors plan to explore the impact of probiotics on GBS colonization in pregnant 
women. It is hoped that the prenatal use of probiotics will alter the maternal gut and vaginal flora to 
reduce the incidence of GBS colonization in late pregnancy. 
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